Our lead clinical candidate is APPA, a combination of 2 synthetic molecules, demonstrating a low risk adverse event profile.
APPA has demonstrated significant analgesic and disease modification effects:
- Repeated, significant pain relief and function improvement in a canine OA model; and in client owned dogs with naturally occurring OA, beyond that of the NSAID standard of care meloxicam
- Disease modification (slowing of cartilage destruction) in the rat meniscal tear model
- Anecdotal evidence of improved functionality and good tolerability in human named patient subjects